

Frontier Fund

A non-dilutive investment fund from the Global Health Investment Corporation (GHIC)



ABOUT GHIC & FRONTIER FUND

GHIC is a mission driven investment firm aiming to catalyze the development of products and technologies to improve global health and strengthen global health security. Under GHIC, the Frontier Fund supports earlier-stage programs to advance novel medical countermeasures that strengthen and expand our capabilities to respond to the growing complexity and unpredictability of health security threats and scenarios.

WHAT IS HEALTH SECURITY

Health security refers to the protection of civilians from health security threats—such as infectious diseases, biological, chemical, and radiological hazards—through the ability to prevent, detect, respond, and recover from these risks effectively. Health security focuses on improving health outcomes for all civilians and increasing the resilience of health systems under a security threat.

TARGET PROGRAM OUTCOMES

The Frontier Fund will support early stage programs to explore and/or validate new applications and capabilities for health security. Early stage programs arising from academic research labs / institutes will be supported to encourage company formation. Early programs led by seed-stage companies will be supported to generate data that will lead to Series A financing. Established companies will be encouraged to explore applications of their platforms or technologies as demonstration projects for health security.



ACADEMIC RESEARCHERS

COMPANY FORMATION

Sponsored research generates data that leads to new company formation.



SEED-STAGE COMPANIES

VENTURE FINANCING

Early-stage company generates data that mobilizes larger venture financing.



ESTABLISHED COMPANIES

PROVEN APPLICATION

Established platform demonstrates applicability to health security.

IMPACT METRICS

new IP filings


products derisked or advanced through development

new companies advanced in stage and financing

Magnitude of ecosystem impact (e.g., # of publications, roundtables, and conferences)

FUNDING AVAILABILITY

The Frontier Fund will target projects that can be completed in 6 - 18 months. The total budget per project will be between \$250k - \$1M depending on the scale and scope of the project as well as strategic priorities. Project funding will be dispersed based on agreed upon milestones. For illustrative purposes, the diagram below provides a framework for proposal assessment and selection.



2025 PRIORITY PROJECT TOPICS

The Frontier Fund will consider a wide range of innovative projects that will lead to the development of high-priority and high-impact medical countermeasures. The project topics listed below are active areas of consideration. Other health security project topics can be submitted for consideration.

Antiviral therapeutics

We are seeking early programs on the discovery, design, and/or development of new classes of antiviral therapeutics. The target therapeutic window is peak viremia. The preferred product exhibits broad spectrum activity against priority pathogens. Priority pathogens include influenza, viral hemorrhagic fevers, and mosquito-vector transmitted infectious diseases.

Examples:

- Highly evolvable platforms to rapidly discover new therapeutics and related derivatives
- "Never done before" applications of innovative platforms to viral targets
- Antigen and/or epitope discovery to guide or accelerate therapeutic development

Novel anti-inflammatories

We are seeking early programs on the discovery, design, and/or development of new anti-inflammatory therapeutics to prevent severe inflammatory disease after opportunistic infections. The target therapeutic window is early, mid, and/or late stages of cytokine storm. Preferred product characteristics include fast acting activity, broad applicability across patient profiles, and strong safety profile.

Examples:

- Immune cells signaling inhibitors and immune modulators
- Targeted cell reprogramming
- Regenerative cytokines and proteins to promote healing
- New classes of anti-inflammatory therapeutics